Kenya Oncology Clinical Trials Market Report 2022 to 2030

Kenya Oncology Clinical Trials Market Analysis

$ 3999

Kenya's oncology clinical trials market is projected to grow from $8.86 Mn in 2022 to $14.8 Mn by 2030, registering a CAGR of 6.6% during the forecast period of 2022-30. The market will be driven by the country's high cancer burden and increased interest in conducting clinical trials in the nation by global pharmaceutical corporations. The market is segmented by phase, study design, and indication. Some of the major players include Pfizer Inc., Roche Holding AG, and Novartis International AG.

ID: IN10KECT006 CATEGORY: Clinical Trials GEOGRAPHY: Kenya AUTHOR: Vidhi Upadhyay

Buy Now

Kenya Oncology Clinical Trials Market Executive Summary

Kenya's oncology clinical trials market is projected to grow from $8.86 Mn in 2022 to $14.8 Mn by 2030, registering a CAGR of 6.6% during the forecast period of 2022-30. Kenya was the third biggest economy in Sub-Saharan Africa as of 2020, after only Nigeria and South Africa. In Kenya, noncommunicable diseases (NCDs) account for 37% of DALYs. In Kenya, the likelihood of acquiring cancer before the age of 75 years (%) is 18% for women and 14.3% for men, while the risk of dying from cancer before the same age is 12.7% for women and 10.3% for men. The five most common cancers in Kenya for both sexes are breast, cervical, prostate, oesophageal, and colorectal.

The environment for oncology clinical trials in Kenya is still developing, although there has been a surge in interest in cancer research and therapy in recent years. Cancer is a major problem in the nation. Several hospitals and research centers in Kenya such as Aga Khan University Hospital, Kenyatta National Hospital, Kenya Medical Research Institute & University of Nairobi are involved in oncology clinical trials. While the oncology clinical trials scenario in Kenya has both opportunities and challenges, the country's increased interest in cancer research and therapy, as well as its dedication to establishing its research infrastructure, implies that it has the possibility of becoming a significant player in the global oncology research landscape.

kenya oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Many reasons are driving the expansion of oncology clinical trials in Kenya. One of the primary factors is the country's high cancer burden, which has led to an increase in interest in cancer research and treatment among researchers, doctors, and legislators. This has resulted in high demand for novel treatments as well as a better knowledge of the genetic and molecular pathways behind various forms of cancer in the Kenyan population. Another driver of oncology clinical trials in Kenya is the increased interest in conducting clinical trials in the nation by global pharmaceutical corporations. As Kenya's healthcare system develops and improves, pharmaceutical firms are more interested in establishing a presence in the nation and undertaking clinical studies focusing on cancer treatment and prevention.

Market Restraints

There are also various barriers to the expansion of oncology clinical trials in Kenya. Scarcity of skilled professionals, such as clinical trial coordinators, data managers, and regulatory specialists. This may make conducting clinical studies that fulfill international standards and regulatory criteria challenging. Another constraint is the scarcity of financing for clinical trials, especially for smaller or independent research institutes. This may make conducting high-quality clinical studies that match international requirements and capture the attention of multinational pharmaceutical corporations challenging.

Competitive Landscape

Key Players

Pfizer Inc.
Roche Holding AG
Novartis International AG
AstraZeneca plc
Merck & Co., Inc.
Eli Lilly and Company
Sanofi S.A.
Bristol Myers Squibb Company

Notable Insights

February 2023, The Aga Khan University Hospital, Nairobi (AKUH, N) has initiated the first cancer drug clinical trial in Africa to test the efficacy of a novel medicine that inhibits the function of a gene mutation that causes cancer in affected patients. AKUH, N is Africa's sole location chosen for the trial of this novel medicine.
February 2023, The Aga Khan University Hospital in Nairobi, Kenya, has started a clinical study in solid tumors using Roche's experimental KRAS G12C inhibitor GDC-6036.
November 2022, The University of Nairobi, via the University of Nairobi Institute of Tropical and Infectious Diseases (UNITID), and Roche signed an MoU to collaborate. While commenting on this relationship, Prof. Julius Oyugi, Director of UNITID, revealed that Roche has recognized UNITID as a viable partner to cooperate with on clinical studies on cancer drugs beginning in January 2023.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.